| Literature DB >> 34212214 |
Manisha Gupta1, Pawan Krishan2, Amarjot Kaur1, Sandeep Arora1, Nirupma Trehanpati3, Thakur Gurjeet Singh1, Onkar Bedi4,5.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the pathogenesis of NAFLD and other metabolic disorders. However, recent scientific upsurge emphasizes on the utility of beneficial gut microbiota and bacteriotherapy in the management of NAFLD. Fecal microbiota transplantation (FMT) is the contemporary therapeutic approach with state-of-the-art methods for the treatment of NAFLD. Other potential therapies include probiotics and prebiotics supplements which are based on alteration of gut microbes to treat NAFLD. In this review, our major focus is on the pathological association of gut microbiota with progression of NAFLD, historical aspects and recent advances in FMT with possible intervention to combat NAFLD and its associated metabolic dysfunctions.Entities:
Keywords: Fecal microbiota transplantation (FMT); Gut microbiota; Non-alcoholic fatty liver diseases (NAFLD); Non-alcoholic steatohepatitis (NASH)
Mesh:
Year: 2021 PMID: 34212214 DOI: 10.1007/s00011-021-01480-z
Source DB: PubMed Journal: Inflamm Res ISSN: 1023-3830 Impact factor: 4.575